Ionis Pharmaceuticals IONS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaborative Agreement Revenue | $541.42M+16.2% | $465.79M-8.7% | $510.28M-2.6% | $523.73M+59.5% | $328.33M-1.3% | |
| Commercial | $467.49M+7.3% | $435.85M+14.6% | $380.24M+11.7% | $340.37M+9.9% | $309.65M+5.7% | |
| Other Commercial | $35.82M+2.3% | $35M-2.2% | $35.8M-2.2% | $36.62M+17.1% | $31.28M-12.6% | |
| Other Royalties | $21.28M-11.9% | $24.16M+9.2% | $22.12M+11.3% | $19.87M+10.5% | $17.99M-14.4% | |
| Research And Development Revenue | $590.7M+16.3% | $507.86M-13.4% | $586.72M-2.8% | $603.68M+48.1% | $407.6M-1.1% | |
| Royalty | $279.69M-2.0% | $285.53M-0.5% | $287.08M+3.2% | $278.2M+2.2% | $272.09M+5.7% | |
| Spinraza Royalties | $207.98M-2.0% | $212.28M-4.3% | $221.93M-0.6% | $223.24M-1.1% | $225.65M+4.4% | |
| Wainua Joint Development Revenue | $49.29M+17.1% | $42.08M-45.0% | $76.44M-4.4% | $79.95M+0.9% | $79.27M-0.2% | |
| Wainus Royalties | $50.43M+2.7% | $49.09M+14.1% | $43.04M+22.7% | $35.09M+23.3% | $28.45M+40.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ionis Pharmaceuticals break its business down?
- Ionis Pharmaceuticals (IONS) reports revenue by product across 11 parts — Collaborative Agreement Revenue, Commercial, DAWNZERA Sales, Other Commercial and Other Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Ionis Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ionis Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
